Compare Ishares Msci Brazil ETF (EWZ) vs Novavax Inc (NVAX) Price & Performance

EWZ, the iShares MSCI Brazil ETF, trades at $33.94, down 3.55% today, with a bearish technical signal driven by moving averages. The ETF faces headwinds from US tariffs on Brazilian goods and mixed sentiment, though oscillators suggest potential near-term support. A dividend of $0.33 is scheduled for June 2026, while institutional investors like Empowered Funds LLC have recently increased positions, indicating some confidence in Brazilian equity value.

The outlook for EWZ hinges on Brazil's economic policies and commodity markets, offering exposure to emerging market growth but with volatility risks from trade tensions and currency fluctuations. Investors should weigh the ETF's high expense ratio against alternatives like FLBR, which offers lower costs and higher dividends, as noted in recent analyst comparisons.

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.